These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10617083)

  • 61. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
    Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
    Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery.
    Benouchan M; Do Nascimento F; Sebbah-Louriki M; Salzmann JL; Crépin M; Perret GY; Colombo BM
    Biochem Biophys Res Commun; 2003 Nov; 311(4):822-8. PubMed ID: 14623255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture.
    Li Z; Han J; Jiang Y; Browne P; Knox RJ; Hu L
    Bioorg Med Chem; 2003 Sep; 11(19):4171-8. PubMed ID: 12951148
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
    de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW
    J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
    Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Selective Cell Ablation Using an Improved Prodrug-Converting Nitroreductase.
    Mulligan TS; Mumm JS
    Methods Mol Biol; 2024; 2707():223-234. PubMed ID: 37668916
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
    Friedlos F; Court S; Ford M; Denny WA; Springer C
    Gene Ther; 1998 Jan; 5(1):105-12. PubMed ID: 9536271
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
    Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
    Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
    Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
    Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
    Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.
    Shibata T; Giaccia AJ; Brown JM
    Neoplasia; 2002; 4(1):40-8. PubMed ID: 11922390
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.
    Theys J; Pennington O; Dubois L; Anlezark G; Vaughan T; Mengesha A; Landuyt W; Anné J; Burke PJ; Dûrre P; Wouters BG; Minton NP; Lambin P
    Br J Cancer; 2006 Nov; 95(9):1212-9. PubMed ID: 17024128
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
    Denny WA; Wilson WR
    J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
    Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD
    Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phthalimide analogs of CB 1954: synthesis and bioactivation.
    Mehta LK; Hobbs S; Chen S; Knox RJ; Parrick J
    Anticancer Drugs; 1999 Sep; 10(8):777-83. PubMed ID: 10573210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
    Mauger AB; Burke PJ; Somani HH; Friedlos F; Knox RJ
    J Med Chem; 1994 Oct; 37(21):3452-8. PubMed ID: 7932574
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
    Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
    Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
    Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
    Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.